AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22537763 — intervention group
Group type: EXPERIMENTAL
Intervention: 16α‐OH pathway
Number of subjects: 188
Study 22537763 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐OH pathway, testosterone, and progesterone
Number of subjects: 188
Study 22537763 — intervention group
Group type: EXPERIMENTAL
Intervention: Size of the dense area
Number of subjects: 188
Study 22537763 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dense area
Number of subjects: 188
Study 19079146 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap on technique
Number of subjects: 8
Study 19079146 — intervention group
Group type: COMPARATOR
Intervention: Flap off technique
Number of subjects: 8
Study 17479609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate
Number of subjects: 0
Study 17479609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11185665 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe2+ form of elemental iron, 7.5 mg daily
Number of subjects: 0
Study 11185665 — intervention group
Group type: COMPARATOR
Intervention: Nonionic trivalent iron (FeIII) complexed with polysaccharides, 7.5 mg daily
Number of subjects: 0
Study 9124858 — intervention group
Group type: EXPERIMENTAL
Intervention: CP following oral administration of diltiazem (60 mg)
Number of subjects: 12
Study 9124858 — intervention group
Group type: EXPERIMENTAL
Intervention: CP following oral administration of nifedipine (20 mg)
Number of subjects: 12
Study 9124858 — intervention group
Group type: COMPARATOR
Intervention: CP alone
Number of subjects: 12
Study 1568367 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam
Number of subjects: 0
Study 1568367 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid
Number of subjects: 0
Study 3893511 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 2 g of sulfametopyrazine
Number of subjects: 42
Study 3893511 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin 250 mg thrice daily for 7 days
Number of subjects: 42
Study 28419732 — intervention group
Group type: COMPARATOR
Intervention: Retosiban (6 mg/h infusion for 24 hours, followed by 12 mg/h infusion over the next 24 hours; preceded by a 6 mg loading dose over 5 minutes)
Number of subjects: 0
Study 28419732 — intervention group
Group type: COMPARATOR
Intervention: Retosiban
Number of subjects: 0
Study 26712227 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term rituximab maintenance (4 administrations every 2 months)
Number of subjects: 270
Study 26712227 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term rituximab maintenance (maximum of 5 years or until disease progression)
Number of subjects: 270
Study 26712227 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term rituximab maintenance
Number of subjects: 270
Study 26712227 — intervention group
Group type: COMPARATOR
Intervention: Short-term rituximab maintenance
Number of subjects: 270
Study 26712227 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 270
Study 24888381 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral simvastatin 40 mg at night for 12 months
Number of subjects: 60
Study 24888381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21941231 — intervention group
Group type: EXPERIMENTAL
Intervention: Vein Viewer
Number of subjects: 115
Study 21941231 — intervention group
Group type: COMPARATOR
Intervention: Standard technique (Control)
Number of subjects: 115
Study 19946776 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate 1,200 mg and vitamin D3 400 IU (10 microg)
Number of subjects: 64
Study 19946776 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 64
Study 18665021 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate 160 mg IM
Number of subjects: 82
Study 18665021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 16037175 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral position (L group)
Number of subjects: 74
Study 16037175 — intervention group
Group type: COMPARATOR
Intervention: Seated position (S group)
Number of subjects: 74
Study 11922555 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide acetate (100 microg i.v.)
Number of subjects: 38
Study 11922555 — intervention group
Group type: COMPARATOR
Intervention: i.v. saline (control)
Number of subjects: 38
Study 10334683 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DRB1-matched blood transfusion
Number of subjects: 40
Study 10334683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8950666 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback closed loop traction control
Number of subjects: 24
Study 8950666 — intervention group
Group type: COMPARATOR
Intervention: Conventional open loop traction control
Number of subjects: 24
Study 1835619 — intervention group
Group type: EXPERIMENTAL
Intervention: Sizofiran (SPG) administered with antitumour drugs
Number of subjects: 386
Study 1835619 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sizofiran)
Number of subjects: 386
Study 31828878 — intervention group
Group type: EXPERIMENTAL
Intervention: RV apical pacing
Number of subjects: 50
Study 31828878 — intervention group
Group type: COMPARATOR
Intervention: RV septal pacing
Number of subjects: 50
Study 31828878 — intervention group
Group type: COMPARATOR
Intervention: Comparison of RV apical and RV septal pacing
Number of subjects: 50
Study 29725846 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% BISA mouthwash
Number of subjects: 30
Study 29725846 — intervention group
Group type: COMPARATOR
Intervention: 0.12% chlorhexidine mouthwash
Number of subjects: 30
Study 29725846 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine + 0.5% BISA mouthwash
Number of subjects: 30
Study 27628168 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity promotion intervention (exercise program of 1-hour sessions twice a week for a year)
Number of subjects: 160
Study 27628168 — intervention group
Group type: COMPARATOR
Intervention: Control group (received recommendations about an active lifestyle from their physicians)
Number of subjects: 160
Study 25961184 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet plus olive oil
Number of subjects: 447
Study 25961184 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet plus nuts
Number of subjects: 447
Study 25961184 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 447
Study 23392270 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg simvastatin daily (high dose) over 3 weeks
Number of subjects: 240
Study 23392270 — intervention group
Group type: COMPARATOR
Intervention: 40 mg simvastatin daily (normal dose)
Number of subjects: 240
Study 20674311 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 30 mg
Number of subjects: 19
Study 20674311 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 90 mg
Number of subjects: 19
Study 20674311 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 270 mg
Number of subjects: 19
Study 20674311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 21798991 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 17-28 hours)
Number of subjects: 227
Study 21798991 — intervention group
Group type: COMPARATOR
Intervention: Two-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 41-45 hours)
Number of subjects: 227
Study 21798991 — intervention group
Group type: COMPARATOR
Intervention: Two-day interval
Number of subjects: 227
Study 21798991 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day interval
Number of subjects: 227
Study 21798991 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day interval among women without previous vaginal deliveries
Number of subjects: 227
Study 21798991 — intervention group
Group type: COMPARATOR
Intervention: Two-day interval among women without previous vaginal deliveries
Number of subjects: 227
Study 21798991 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day interval when gestation exceeded 16 weeks
Number of subjects: 227
Study 21798991 — intervention group
Group type: COMPARATOR
Intervention: Two-day interval when gestation exceeded 16 weeks
Number of subjects: 227
Study 17702040 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (5,000 units, three times weekly subcutaneously)
Number of subjects: 12
Study 17702040 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Number of subjects: 12
Study 15599490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SNB) without elective neck dissection
Number of subjects: 70
Study 15599490 — intervention group
Group type: COMPARATOR
Intervention: Postoperative observation of neck node metastases
Number of subjects: 70
Study 12225327 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus interferon (CIFN) induction therapy for one month followed by standard 9 microg of CIFN thrice weekly for 11 months
Number of subjects: 173
Study 12225327 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid viral response (RVR) during the first month of induction dosing
Number of subjects: 173
Study 12225327 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction dosing with CIFN
Number of subjects: 173
Study 12225327 — intervention group
Group type: EXPERIMENTAL
Intervention: Early viral kinetics during the first month of therapy
Number of subjects: 173
Study 15641227 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication treatment (Pantoprazole 40 mg 1x/day, Amoxycillin 1000 2x/day, Claritromycin 500 2x/day)
Number of subjects: 251
Study 8787478 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 20
Study 8787478 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (hyperventilation, inspired oxygen fraction of 0.80, and inotropic agents)
Number of subjects: 20
Study 2313319 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney Disease Questionnaire (KDQ)
Number of subjects: 0
Study 2313319 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental education program
Number of subjects: 0
Study 2313319 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting dialysis
Number of subjects: 0
Study 7440192 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (3 x 5000 IU/day)
Number of subjects: 227
Study 7440192 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (2 x 5000 IU/day) + 0.5 mg dihydroergot (DHE)
Number of subjects: 227
Study 7440192 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy (intermittent compression stockings + physical exercise)
Number of subjects: 227
Study 7440192 — intervention group
Group type: COMPARATOR
Intervention: Phlebography
Number of subjects: 227
Study 7440192 — intervention group
Group type: COMPARATOR
Intervention: Doppler
Number of subjects: 227
Study 31812878 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibudilast (IBUD)
Number of subjects: 11
Study 31812878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31546685 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning exercise group
Number of subjects: 71
Study 31546685 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening exercise group
Number of subjects: 71
Study 31546685 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 71
Study 28938219 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.5mg/kg
Number of subjects: 104
Study 28938219 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 104
Study 28938219 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 104
Study 26416604 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 732
Study 26416604 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet
Number of subjects: 732
Study 26416604 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 732
Study 26416604 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet
Number of subjects: 732
Study 22886533 — intervention group
Group type: EXPERIMENTAL
Intervention: CT in the trauma room
Number of subjects: 1124
Study 21078382 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic methylation to dimethylarsinic acid (DMA)
Number of subjects: 324
Study 21078382 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic methylation to monomethylated metabolite
Number of subjects: 324
Study 21078382 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status (including vitamin B12 and folate)
Number of subjects: 324
Study 21078382 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary excretion of arsenic
Number of subjects: 324
Study 19844090 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with B. lactis
Number of subjects: 525
Study 19844090 — intervention group
Group type: COMPARATOR
Intervention: Formula without B. lactis
Number of subjects: 525
Study 16915978 — intervention group
Group type: EXPERIMENTAL
Intervention: Function-related tests (hand to neck, hand to scapula, hand to opposite scapula)
Number of subjects: 46
Study 15260876 — intervention group
Group type: EXPERIMENTAL
Intervention: High DHA levels in mothers at birth
Number of subjects: 0
Study 15260876 — intervention group
Group type: COMPARATOR
Intervention: Low DHA levels in mothers at birth
Number of subjects: 0
Study 11753595 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily
Number of subjects: 294
Study 11753595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study 11753595 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat during extension phase
Number of subjects: 294
Study 11753595 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 294
Study 9425508 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous risedronate 2.5 mg
Number of subjects: 132
Study 9425508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic risedronate 2.5 mg
Number of subjects: 132
Study 9425508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 8503714 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg verapamil
Number of subjects: 40
Study 8503714 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg enalapril
Number of subjects: 40
Study 8503714 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs simultaneously
Number of subjects: 40
Study 8503714 — intervention group
Group type: COMPARATOR
Intervention: Both products (verapamil and enalapril)
Number of subjects: 40
Study 3620826 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix (320 mg iodine/ml)
Number of subjects: 97
Study 3620826 — intervention group
Group type: COMPARATOR
Intervention: Iopamiron (300 mg iodine/ml)
Number of subjects: 97
Study 3620826 — intervention group
Group type: COMPARATOR
Intervention: iohexol (300 mg iodine/ml)
Number of subjects: 97
Study 29329567 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week course of Modified Pilates (MP) classes in addition to standard physiotherapy care
Number of subjects: 73
Study 29329567 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy care only
Number of subjects: 73
Study 27302000 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled infusion (TCI) of propofol
Number of subjects: 77
Study 27302000 — intervention group
Group type: COMPARATOR
Intervention: Fractionated propofol administration (FPA)
Number of subjects: 77
Study 24925227 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally and linguistically tailored telephone-delivered intervention; 10 phone calls to address challenges and barriers to care
Number of subjects: 0
Study 24925227 — intervention group
Group type: COMPARATOR
Intervention: Attention-control arm
Number of subjects: 0
Study 23250252 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure measurement (HBPM) with educational activities
Number of subjects: 290
Study 23250252 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control group)
Number of subjects: 290
Study 20513222 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO)
Number of subjects: 3
Study 20513222 — intervention group
Group type: COMPARATOR
Intervention: Conventional Ventilation
Number of subjects: 3
Study 19010947 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich diet
Number of subjects: 7
Study 19010947 — intervention group
Group type: COMPARATOR
Intervention: Protein-rich diet
Number of subjects: 7
Study 16221311 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioner care plus a program of care based on the McKenzie Method
Number of subjects: 148
Study 16221311 — intervention group
Group type: COMPARATOR
Intervention: General practitioner care
Number of subjects: 148
Study 12163917 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ) - 30 mg/kg body weight in three divided daily doses
Number of subjects: 191
Study 12163917 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP) - 25 mg/kg body weight of sulfadoxine and 1.25 mg/kg of pyrimethamine in a single oral dose
Number of subjects: 191
Study 12163917 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine-amodiaquine combination (SP+AQ) - same doses as in SP and AQ, given simultaneously on day 0
Number of subjects: 191
Study 10408318 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate beverage ingestion (C)
Number of subjects: 10
Study 10408318 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage ingestion (P)
Number of subjects: 10
Study 7587701 — intervention group
Group type: EXPERIMENTAL
Intervention: B ultrasound
Number of subjects: 41
Study 7587701 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan
Number of subjects: 41
Study 7587701 — intervention group
Group type: EXPERIMENTAL
Intervention: Thallium-technetium scanning (TTS)
Number of subjects: 41
Study 2328557 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day fluoxetine
Number of subjects: 29
Study 2328557 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day fluoxetine
Number of subjects: 29
Study 2328557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 376894 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 44
Study 376894 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine and aminophylline
Number of subjects: 44
Study 31846088 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish protein hydrolysate (FPH)
Number of subjects: 9
Study 31846088 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein hydrolysate (WPH)
Number of subjects: 9
Study 31846088 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 9
Study 29483485 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminoplasty in patients with kyphosis and CSM (KC group)
Number of subjects: 137
Study 29483485 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminoplasty in patients with lordosis and CSM (LC group)
Number of subjects: 137
Study 29483485 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminoplasty in patients with kyphosis and OPLL (KO group)
Number of subjects: 137
Study 29483485 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminoplasty in patients with lordosis and OPLL (LO group)
Number of subjects: 137
Study 26427719 — intervention group
Group type: EXPERIMENTAL
Intervention: Students for Nutrition and eXercise (SNaX) intervention
Number of subjects: 1520
Study 25580087 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine treatment to maintain StO2 ≥ 80%
Number of subjects: 50
Study 25580087 — intervention group
Group type: COMPARATOR
Intervention: Standard care algorithm
Number of subjects: 50
Study 25580087 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine treatment
Number of subjects: 50
Study 22814041 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery with iStent trabecular micro-bypass stent implantation
Number of subjects: 0
Study 22814041 — intervention group
Group type: COMPARATOR
Intervention: Cataract surgery alone
Number of subjects: 0
Study 20386555 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment arm
Number of subjects: 50
Study 20386555 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 50
Study 20386555 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids before study entry
Number of subjects: 50
Study 20386555 — intervention group
Group type: EXPERIMENTAL
Intervention: Spine surgery before enrollment
Number of subjects: 50
Study 18339790 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled mannitol (420 mg, twice daily for 2 weeks)
Number of subjects: 39
Study 18339790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 15975155 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (50 g carbohydrate drink)
Number of subjects: 10
Study 15975155 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (50 g carbohydrate drink)
Number of subjects: 10
Study 15975155 — intervention group
Group type: COMPARATOR
Intervention: Water (300 ml)
Number of subjects: 10
Study 15975155 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (50 g carbohydrate drink)
Number of subjects: 10
Study 12788569 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 5165
Study 11424660 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol levels in patients with unstable coronary disease (group I)
Number of subjects: 75
Study 11424660 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol levels in patients with acute myocardial infarction (group II)
Number of subjects: 75
Study 11424660 — intervention group
Group type: COMPARATOR
Intervention: Cortisol levels in healthy volunteers (control group)
Number of subjects: 75
Study 8785133 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine 0.15 mg kg‐1 i.v. at peritoneal closure after hysterectomy (group post)
Number of subjects: 60
Study 8785133 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine 0.15 mg kg‐1 on induction of anaesthesia (group pre‐low)
Number of subjects: 60
Study 8785133 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine 0.3 mg kg‐1 on induction of anaesthesia (group pre‐high)
Number of subjects: 60
Study 8785133 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine 0.3 mg kg‐1 i.v. on induction of anaesthesia (group pre‐high)
Number of subjects: 60